Brain Fog (Difficulty Thinking Clearly) Mega Study
Contents
Brain Fog (Difficulty Thinking Clearly)
Brain Fog (Difficulty Thinking Clearly)

Tags

Brain Fog
difficulty Thinking Clearly
Brain Fog (Difficulty Thinking Clearly)

Abstract

This mega-study analyzes Brain Fog (Difficulty Thinking Clearly) (Symptoms) using aggregated N-of-1 observational data from 106 participants who contributed 506 measurements . We identified 379 statistically significant predictor-outcome relationships involving Brain Fog (Difficulty Thinking Clearly).

Brain Fog (Difficulty Thinking Clearly) acts as both a predictor (affecting 72 outcomes) and an outcome (influenced by 307 factors). Effect sizes are reported as percent change from baseline, enabling direct comparison across measures.

Our analysis employs within-subject comparisons to control for individual differences, temporal precedence analysis to assess causality direction, and the Predictor Impact Score (PIS) to quantify causal evidence. See the ranked results below to explore the full list of factors predicting Brain Fog (Difficulty Thinking Clearly).

Keywords: Brain Fog (Difficulty Thinking Clearly), Symptoms, N-of-1 trials, real-world evidence, causal inference, Predictor Impact Score, observational study

Full Methodology: Framework for Real-World Evidence-Based Pharmacovigilance: Aggregated N-of-1 Trials for Quantifying Treatment Effects

High Confidence: With 106 participants, these findings have strong statistical power. Results are significant at p < 0.05.

Results

Our analysis identified 379 statistically significant relationships involving Brain Fog (Difficulty Thinking Clearly). This includes 72 outcomes affected by Brain Fog (Difficulty Thinking Clearly) and 307 predictors of Brain Fog (Difficulty Thinking Clearly).

Click any relationship in the tables below to view the full study page with detailed charts, statistical analysis, temporal parameters, and methodology for that specific predictor-outcome pair.

Relationship Network

The network graph below visualizes the relationships between Brain Fog (Difficulty Thinking Clearly) and related variables. Nodes represent variables, and edges represent statistically significant relationships. Click any node or edge to explore that relationship.

Causal Flow Diagram

The Sankey diagram below illustrates the flow of influence between predictors, Brain Fog (Difficulty Thinking Clearly), and outcomes. The width of each flow corresponds to the strength of the relationship. Click any flow to see the detailed study.

Predictors of Brain Fog (Difficulty Thinking Clearly)

The table below ranks predictors by their impact on Brain Fog (Difficulty Thinking Clearly). Each row shows the percent change in Brain Fog (Difficulty Thinking Clearly) following above-average predictor exposure. Click any row to see the full analysis.

PUZZLED_ROBOT
Don't see what you're looking for?

Less than 1% of patients are able to participate in clinical trials! :(

Take 30 seconds to make it possible for all patients to easily participate in trials for the most promising treatments!

Predictors
of
Below is the change in after each predictor is higher than average.
Sort by % Change
Sort by Evidence
Sort by Participants
Predictor
% Change from Baseline
*
Change from average after above-average predictor exposure.
Note: Results are based on aggregated observational data. Confidence increases with more participants. Click any row for full study details.

Summary Statistics

Brain Fog (Difficulty Thinking Clearly) Info

Property Value
Variable Name Brain Fog (difficulty Thinking Clearly)
Aggregation Method MEAN
Analysis Performed At 2020-10-11
Duration of Action 24 hours
Kurtosis 1.5439155850678
Maximum Allowed Value 5 out of 5
Mean 3.4220148648649 out of 5
Median 3.415627027027 out of 5
Minimum Allowed Value 1 out of 5
Number of Aggregate Predictors 307
Number of Aggregate Outcomes 72
Number of Measurements 506
Number of Measurements (including those generated by tagged, joined, or child variables) 506
Public true
Onset Delay 0 seconds
Standard Deviation 0.4041311973139
Unit 1 to 5 Rating
User Variables 106
UPC 0
Variable Category Symptoms
Variable ID 88305
Variance 0.40201953169415

Introduction

Background

Brain Fog (Difficulty Thinking Clearly) (Symptoms) acts as both a modifiable factor (predictor) and a measurable health outcome. Understanding the predictors and outcomes associated with Brain Fog (Difficulty Thinking Clearly) has important implications for personalized health optimization, clinical decision-making, and public health interventions. Traditional randomized controlled trials (RCTs), while the gold standard for causal inference, are often impractical for studying the full range of factors that may influence symptoms.

Research Questions

This mega-study addresses the following research questions:

  1. What factors most strongly predict changes in Brain Fog (Difficulty Thinking Clearly)?
  2. What health outcomes are most affected by changes in Brain Fog (Difficulty Thinking Clearly)?
  3. What is the magnitude of these effects (percent change from baseline)?
  4. How confident can we be in these relationships?

Study Overview

We employ an aggregated N-of-1 observational study design, combining data from multiple individual longitudinal natural experiments. This approach leverages within-subject comparisons to control for stable individual differences while aggregating across participants to identify population-level patterns.

Discussion

Interpretation of Findings

The ranked tables in the Results section provide a comprehensive list of predictors, ordered by their effect size on Brain Fog (Difficulty Thinking Clearly). Rather than focusing on any single relationship, the value lies in the full spectrum of factors identified and their relative effect sizes.

Context and Prior Research

These findings should be interpreted in the context of existing literature on Brain Fog (Difficulty Thinking Clearly). While our observational design cannot establish causality with the certainty of randomized trials, the large sample size, within-subject design, and temporal precedence analysis provide converging evidence for the relationships identified.

Practical Implications

Individuals seeking to optimize their Brain Fog (Difficulty Thinking Clearly) may consider the predictors identified in this analysis, particularly those that are directly modifiable (e.g., behaviors, treatments, environmental factors). However, individual responses may vary, and these population-level findings should not replace personalized medical advice.

Future Directions

Future research should examine:

  • Subgroup analyses to identify individual differences in response
  • Potential confounders and mediators of the observed relationships
  • Optimal dosing and timing for modifiable predictors
  • Confirmation of key findings through prospective or randomized designs

Conclusion

The ranked tables above provide the complete list of factors predicting Brain Fog (Difficulty Thinking Clearly), ordered by effect size.

These findings may inform evidence-based strategies for optimizing Brain Fog (Difficulty Thinking Clearly). Individual responses may vary; consult healthcare providers for personalized guidance.

Help End Unnecessary Suffering

Current clinical trials are 82x more expensive than necessary and take 17 years to bring treatments to market. Pragmatic trials integrated into standard healthcare could reduce costs from $41,000 to $500 per participant and compress timelines to just 2 years. Learn how redirecting just 1% of global military spending could accelerate cures for the 2 billion people suffering from treatable diseases.

Methods

Study Design

Our analysis of Brain Fog (Difficulty Thinking Clearly) is based on aggregated data from 106 separate N-of-1 observational natural experiments. Unlike traditional clinical trials, our approach captures relationships in everyday life conditions, providing insights into how factors actually affect people outside controlled laboratory settings. Each participant serves as their own control, reducing between-subject confounding.

Baseline & Outcome Measurement

For each participant \(i\), we compute the mean predictor value and partition measurements into baseline (below-average exposure) and follow-up (above-average exposure) periods:

$$\text{Baseline}_i = \{(p, o) : p < \bar{p}_i\} \quad \text{Follow-up}_i = \{(p, o) : p \geq \bar{p}_i\}$$

The primary effect size is expressed as percent change from baseline:

$$\Delta\% = \frac{\mu_{\text{follow-up}} - \mu_{\text{baseline}}}{\mu_{\text{baseline}}} \times 100$$

This metric is interpretable ("15% reduction in symptoms"), scale-invariant, and consistent with FDA efficacy assessments.

Temporal Analysis & Causality Direction

Our analysis accounts for two critical temporal parameters:

  • Onset Delay (\(\delta\)): Time lag between predictor exposure and observable outcome change (0-100 days)
  • Duration of Action (\(\tau\)): Time window over which predictor influence persists (10 min - 90 days)

We compute both forward correlations (predictor → outcome) and reverse correlations (outcome → predictor) to calculate the temporality factor:

$$\phi_{\text{temporal}} = \frac{|r_{\text{forward}}|}{|r_{\text{forward}}| + |r_{\text{reverse}}|}$$

A temporality factor approaching 1.0 indicates the predictor reliably precedes the outcome, supporting a causal interpretation. Values near 0.5 suggest ambiguous temporal direction, while values approaching 0 suggest reverse causation.

Temporal Parameter Optimization

Different predictor-outcome pairs have different optimal temporal alignments. We employ hyperparameter optimization to find the onset delay and duration that maximize correlation strength:

$$(\delta^*, \tau^*) = \underset{\delta, \tau}{\text{argmax}} \; |r(\delta, \tau)|$$

The search begins with category-appropriate defaults (e.g., 30-minute onset for treatments) and explores physiologically plausible ranges. To prevent overfitting, we restrict searches to biologically plausible ranges and require minimum sample sizes.

Statistical Methods

We employ multiple statistical techniques:

  • Pearson Correlation Coefficient:
    $$r = \frac{\sum_{j=1}^{n}(p_j - \bar{p})(o_j - \bar{o})}{\sqrt{\sum_{j=1}^{n}(p_j - \bar{p})^2} \cdot \sqrt{\sum_{j=1}^{n}(o_j - \bar{o})^2}}$$
  • Z-Score Normalization: Effect magnitude relative to baseline variability:
    $$z = \frac{|\Delta\%|}{\text{RSD}_{\text{baseline}}}$$
    where \(z > 2\) indicates \(p < 0.05\) (statistically significant)
  • Two-Tailed T-Tests: Statistical significance assessed at \(\alpha = 0.05\)
  • 95% Confidence Intervals: \(\text{CI}_{95\%} = \bar{r} \pm 1.96 \cdot \text{SE}_{\bar{r}}\)

Effect Size Classification

Correlation strength is classified based on the absolute coefficient value:

Classification Correlation Range
Very Strong\(|r| \geq 0.8\)
Strong\(0.6 \leq |r| < 0.8\)
Moderate\(0.4 \leq |r| < 0.6\)
Weak\(0.2 \leq |r| < 0.4\)
Very Weak\(|r| < 0.2\)

Data Quality Requirements

To ensure reliable results, we enforce minimum thresholds:

  • ≥ 5 distinct value changes in both predictor and outcome variables
  • ≥ 30 overlapping measurement pairs (per Central Limit Theorem)
  • ≥ 10% of data in both baseline and follow-up periods
  • Non-zero variance in both predictor and outcome

Our filling strategy is deliberately conservative: zero-filling for treatments assumes non-adherence when no measurement exists, biasing toward null findings rather than false positives.

Predictor Impact Score (PIS)

We calculate a composite Predictor Impact Score that quantifies how much a predictor impacts an outcome:

$$\text{PIS} = |r| \cdot S \cdot \phi_z \cdot \phi_{\text{temporal}} \cdot f_{\text{interest}}$$

Where:

  • \(|r|\) = absolute correlation coefficient (strength)
  • \(S = 1 - p\) = statistical significance
  • \(\phi_z = \frac{|z|}{|z| + 2}\) = normalized z-score factor (effect magnitude)
  • \(\phi_{\text{temporal}}\) = temporality factor (forward vs. reverse causation)
  • \(f_{\text{interest}}\) = interest factor (penalizes spurious variable pairs)

Higher PIS values indicate predictors with greater, more reliable impact on the outcome.

Bradford Hill Criteria for Causality

While correlation does not prove causation, our PIS operationalizes six of the nine Bradford Hill criteria:

Criterion How Addressed Metric
StrengthEffect size magnitude\(|r|\), \(\Delta\%\)
ConsistencyCross-participant replication\(N\), \(n\), SE, CI
TemporalityForward vs. reverse correlation\(\phi_{\text{temporal}}\)
Biological GradientDose-response analysis\(\phi_{\text{gradient}}\)
SpecificityCategory appropriateness\(f_{\text{interest}}\)
PlausibilityCommunity votingUp/down votes

Confidence Levels

Each relationship is assigned a confidence level based on multiple factors:

  • High Confidence: \(p < 0.01\), or \(N > 100\) participants, or \(n > 500\) pairs
  • Medium Confidence: \(p < 0.05\), or \(N > 10\) participants, or \(n > 100\) pairs
  • Low Confidence: Meets minimum thresholds but requires more data

Limitations

Key limitations of this observational framework:

  • Cannot prove causation: Unmeasured confounders may influence results
  • Self-selection bias: Health trackers may differ from general population
  • Measurement error: Self-reported data may contain recall bias
  • Confounding by indication: Sicker patients may take more treatments

These findings represent population-level trends and should not replace personalized medical advice. Within-subject comparison and temporal precedence analysis partially mitigate these limitations.

Population Analysis

With 106 participants contributing data, our analysis benefits from the Law of Large Numbers: as sample size increases, random noise diminishes and true relationships become more apparent. Population-level estimates are computed as:

$$\bar{r} = \frac{1}{N} \sum_{i=1}^{N} r_i \quad \text{with} \quad \text{SE}_{\bar{r}} = \frac{\sigma_r}{\sqrt{N}}$$

Principal Investigator

Program & Methods

Mike P. Sinn

Designed and implemented data collection, aggregation, causal inference pipeline, and automated study generation framework. Developed the Predictor Impact Score methodology operationalizing Bradford Hill criteria for ranking causal relationships in observational data. When he tells people this at parties, they usually say they have to go check on their car.

Individual study outputs are automated, reproducible, and open to external audit. (Which I would seriously recommend.)

Cite This Study

APA Format
Sinn, M. P. (2026). Brain Fog (Difficulty Thinking Clearly) Mega-Study: Systematic Analysis of Causes and Effects [Data set; N=106]. The Journal of Citizen Science. https://studies.crowdsourcingcures.org/variables/Brain_Fog_(difficulty_Thinking_Clearly)
BibTeX
@misc{sinn_88305_2026,
  author = {Sinn, Mike P.},
  title = {Brain Fog (Difficulty Thinking Clearly) Mega-Study: Systematic Analysis of Causes and Effects},
  year = {2026},
  publisher = {The Journal of Citizen Science},
  url = {https://studies.crowdsourcingcures.org/variables/Brain_Fog_(difficulty_Thinking_Clearly)},
  note = {Accessed: January 8, 2026},
  howpublished = {N=106 participants}
}
Chicago/Turabian
Sinn, Mike P. "Brain Fog (Difficulty Thinking Clearly) Mega-Study: Systematic Analysis of Causes and Effects." Data set, N=106. The Journal of Citizen Science. Accessed January 8, 2026. https://studies.crowdsourcingcures.org/variables/Brain_Fog_(difficulty_Thinking_Clearly).
Harvard
Sinn, M.P., 2026. Brain Fog (Difficulty Thinking Clearly) Mega-Study: Systematic Analysis of Causes and Effects. [Aggregated N-of-1 Study, N=106] The Journal of Citizen Science. Available at: https://studies.crowdsourcingcures.org/variables/Brain_Fog_(difficulty_Thinking_Clearly) [Accessed January 8, 2026].

Study Type: Aggregated N-of-1 Observational Mega-Study
Evidence Level: Level II (Real-World Evidence)
Methodology: Bradford Hill Criteria with Predictor Impact Score (PIS)

References

This framework was originally developed in 2013 based on the Bradford Hill criteria. Subsequent literature has independently validated similar approaches to causal inference from observational data:

  1. Hill, A.B. (1965). The environment and disease: association or causation? Proceedings of the Royal Society of Medicine, 58(5), 295-300. [Bradford Hill criteria]
  2. Lillie, E.O., et al. (2011). The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? Personalized Medicine, 8(2), 161-173. [N-of-1 methodology]
  3. Pearl, J. (2009). Causality: Models, Reasoning, and Inference . Cambridge University Press. [Causal inference]
  4. Hernán, M.A., & Robins, J.M. (2020). Causal Inference: What If . Chapman & Hall/CRC. [Free textbook]
  5. FDA (2018). Framework for FDA's Real-World Evidence Program . U.S. Food and Drug Administration. [Regulatory context]
  6. Duan, N., et al. (2013). Single-patient (n-of-1) trials: a pragmatic clinical decision methodology . Journal of Clinical Epidemiology, 66(8), S21-S28.
  7. Platt, R., et al. (2018). The FDA Sentinel Initiative—an evolving national resource . New England Journal of Medicine, 379(22), 2091-2093.

This information is for research and educational purposes only, not medical advice. Consult a healthcare provider before making health decisions. Terms of Service